SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. announced today the appointments of Todd Rich, M.D. to the company's board of directors and Malcolm Lloyd-Smith to the position of Senior Vice President, Regulatory Affairs and Quality Assurance. Mr. Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company for medical reasons.
"We are very pleased to welcome Dr. Rich to our board of directors," stated Cam Garner, Chairman of Cadence. "Todd brings to Cadence a wealth of clinical development, regulatory, and general management expertise, which will be invaluable as we continue to build a world class, hospital-focused biopharmaceutical company."
"Malcolm's extensive regulatory and quality assurance experience is a great asset to Cadence," added James Breitmeyer, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Cadence. "Malcolm will play a key role in helping us achieve our regulatory objectives for our two Phase III product candidates, Acetavance(TM) for the treatment of acute pain and fever, and Omigard(TM) for the prevention of catheter-related infections."
Dr. Rich is currently Vice President, Development Regulatory, Medical Information, Drug Safety, Quality and Compliance at Genentech, Inc. Dr. Rich joined Genentech in 1992 and has served in a variety of roles, including Vice President, Clinical and Commercial Regulatory Affairs and Senior Director, Product Development, where he was the Global Project Team Leader for Rituxan(R) (rituximab). Previously, he was a Staff Physician at St. John's Hospital in Detroit, Michigan. Dr. Rich received his B.S. in biology from Amherst College and his M.S. in biomedical engineering from the University of Michigan. He holds an M.D. from Wayne State University and an M.B.A. from the Stanford University Graduate School of Business.
Mr. Lloyd-Smith joins Cadence from Elan Pharmaceuticals, Inc., where he was most recently Vice President and Head of Global Regulatory Affairs, and where he led the successful filings and approvals of Tysabri(R) (natalizumab) and Prialt(R) (ziconotide) in the United States and Europe. At Elan, he was responsible for the development and implementation of global regulatory strategy for all research and development and commercialization activities, as well as the global management of the pharmacovigilance and medical writing functions. Previously, Mr. Lloyd-Smith held senior regulatory positions with Bristol-Myers Squibb Pharmaceuticals and its predecessor, DuPont Pharmaceuticals, where he was most recently Vice President, Worldwide Regulatory Affairs. He received his M.S. in pharmacological biochemistry from Hatfield Polytechnic and his B.S. in pharmacology from the University of Leeds.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com/.
Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "will," "believe," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding the company's expectations that it will build a world-class biopharmaceutical company and achieve regulatory objectives for its product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: the ability of the company's senior management team, some of whom have limited experience working together as a group, to manage the company's business effectively; the potential for loss of key personnel, which could have an adverse effect on Cadence's ability to execute its business strategy and on its business results; the FDA may require Cadence to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of New Drug Applications, or NDAs, for its product candidates; the company's clinical trials may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials; the outcomes of final analyses of data from Cadence's clinical trials may vary from the initial analyses, and the FDA may not agree with the company's interpretation of such results; clinical trial data for Cadence's product candidates may demonstrate inadequate therapeutic efficacy, or the prevalence or severity of adverse side effects may be greater than anticipated; the company may experience delays in completing important pre- commercialization manufacturing development activities for its product candidates, which may delay the submission of NDAs for its product candidates; Cadence's patent rights may be insufficient to protect its product candidates; the company's product candidates may not compete successfully against existing or new products; Cadence may require substantial additional funding to complete its development programs and, if approved, to successfully launch its product candidates, and it may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases and periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc. Rituxan(R) is a registered trademark of Biogen Idec, Inc. Tysabri(R) and Prialt(R) are registered trademarks of Elan Pharmaceuticals, Inc.
Contacts: William R. LaRue SVP & Chief Financial Officer Cadence Pharmaceuticals, Inc. 858-436-1400 Anna Gralinska Director, Investor Relations Cadence Pharmaceuticals, Inc. 858-436-1452
